// App-Quantinova.ai

POS0931 (2022) : EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL

Researchers

Presenter

  • S. Ramiro

Principal Investigators

  • C. Lukas

  • M. J. Nissen

  • Y. Schymura

  • K. Ng

  • A. Bradley

  • G. Doridot

  • S. Liu Leage

  • A. Chan

  • J. C. C. Wei

Medical Centers

  • Leiden University Medical Center, Department of Immunology, Leiden, Netherlands

  • University of Montpellier, University Hospital Centre Montpellier, Montpellier, France

  • Geneva University Hospitals, Division of Cardiology, Geneva, Switzerland

  • Eli Lilly and Company Corporate Center, Statistics, Indianapolis, United States of America

  • Royal Berkshire Hospital, Department of Rheumatology, Reading, United Kingdom

  • China Medical University, College of Medicine, Taichung, Taiwan, Republic of China

  • China Medical University, Graduate Institute of Integrated Medicine, Taichung, Taiwan, Republic of China

Locations

  • Netherlands

  • France

  • Switzerland

  • United States

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02696785

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved